Is DNA or RNA  abnormalities  resulting from incorporation of false pyrimidines represent an appropriate readout??

The idea is to construct a new dds beased on nanomaterial. I would not care so much about molecular targets,  I would rather focus on the pharmacokinetics and in vivo studies on anticancer activity. In the case of PK studies on oral formulation it is important to remove the whole GI tract for the determination of the %D remaining there.

Thanks so much Dr.Bale,

i will do cell cycle analysis by flowcytometry for the invitro experiments after few hours of exposure. Also invivo pharmacokinetics will be done.

Best Regards